

ICMJE DISCLOSURE FORM

Date: Jan 31, 2023

Your Name: Robert Coleman

Manuscript Title: Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer: editorial commentary

Manuscript number (if known): ATM-2023-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	ACE Oncology	Personal fees for development of medical education programmes
		Sanofi	Personal fees for educational advisory board membership

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Amgen	Personal speaker fees
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	Inbiomotion	MAF Biomarker under development
9	Participation on a Data Safety Monitoring Board or Advisory Board	Astra Zeneca	Personal fees for trial safety committee
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	Inbiomotion	MAF Biomarker under development
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

Professor Coleman has provided consultancy to ACE Oncology and Sanofi for independent medical education programs, received speaker fees from Amgen, holds patent rights and stock options with Inbiomotion for a biomarker in development and received fees from Astra Zeneca for trial safety committee.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.